Intraoperative Pathology Assessment May Lead to Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer Patients Undergoing Upfront Mastectomy-Reference-Cited by-同舟云学术

Intraoperative Pathology Assessment May Lead to Overtreatment of the Axilla in Clinically Node-Negative Breast Cancer Patients Undergoing Upfront Mastectomy

Published:2023-07-12 Issue:10 Volume:30 Page:5978-5987
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Pride Robert M.,Glass Charity C.,Nakhlis Faina,Laws Alison,Weiss Anna C.,Bellon Jennifer R.,Mittendorf Elizabeth A.,King Tari A.,Kantor Olga

Funder

Pamela and Nick Gelsomini Breast Surgical Oncology Fellowship Fund

Rob and Karen Hale Distinguished Chair in Surgical Oncology

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-023-13898-2.pdf

Reference25 articles.

1. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10. https://doi.org/10.1016/S1470-2045(14)70460-7.

2. Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the american college of surgeons oncology group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016;264(3):413–20. https://doi.org/10.1097/SLA.0000000000001863.

3. Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al.,International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23–01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385–93. https://doi.org/10.1016/S1470-2045(18)30380-2.

4. Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla - surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43(4):672–9. https://doi.org/10.1016/j.ejso.2016.12.011.

5. Milgrom S, Cody H, Tan L, Morrow M, Pesce C, Setton J, et al. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol. 2012;19(12):3762–70. https://doi.org/10.1245/s10434-012-2386-3.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should surgeons reconsider the role of intraoperative sentinel lymph node evaluation for premenopausal breast cancer patients in the era of RxPONDER?;The American Journal of Surgery;2024-08

2. Does Neoadjuvant Chemotherapy in Clinical T1–T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?;Annals of Surgical Oncology;2024-01-25

3. 24th Annual Meeting of the American Society of Breast Surgeons (ASBRS): One If by Land, Two If by Sea: ASBRS Rides Into Boston;Annals of Surgical Oncology;2023-08-19